Clinical Trial Update: CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of Vyxeos (CPX-351) is investigating treatment of relapsed or refractory high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Phase 1 | Status: RECRUITING